Evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas’ disease
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Heart failure is a common manifestation of Chagas’ disease and results in significant morbidity and mortality in affected patients. In light of limited data on therapeutic options for heart failure due to Chagas’ disease, the PARACHUTE-HF trial aimed to compare the effects of sacubitril/valsartan versus enalapril on clinical endpoints and changes in natriuretic peptides in this population. This mini-review contextualizes the results of the trial, which demonstrated that sacubitril/valsartan led to significant improvements in outcomes driven primarily by a reduction in natriuretic peptides.
Fields of Study & Subjects
Heart Failure Treatment and Management
Trypanosoma species research and implications
Cardiac Fibrosis and Remodeling
Publication details
- Journal / source
- Heart Failure Reviews
- Volume
- 31
- Issue
- 1
- Pages
- 49
- Publication date
- 30 March 2026
- Language
- EN